• PTC Therapeutics Executive VP and CLO Mark Elliott Boulding reported option exercises, acquiring 10,522 common shares at USD 46.54 on June 17, 2026.
• He also sold 10,462 common shares the same day at weighted average prices of USD 78.5 and USD 79.24.
• Beneficial ownership in common stock ended at 105,272 shares.
• Stock options beneficially owned fell to 30,938 shares, with an additional option line at 32,950 shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001578852-26-000018), on June 22, 2026, and is solely responsible for the information contained therein.